- Featured ads
Prepare on the grounds that the most famous fat consuming weight reduction diet pill in 2021 is coming at you sweltering and hefty, and here is the thing that the exploration is saying about the Meticore morning digestion trigger enhancement up until this point.
- ALK Fusion Probe
ALK Gene Fusion Detection ProbeProduct Advantages:?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.3.Reproducibility: Different laboratories test results are highly reproducibleProduct Description :Lung cancer, Anaplastic large cell lymphomaAbout ALKThe ALK gene encodes a transmembrane receptor tyrosine kinase (RTK). The ALK-NPM1 fusion protein was originally found in anaplastic large cell lymphoma and in other tumors including neuroblastoma and non-small cell lung cancer. The gene was found to be mutated, amplified, or rearranged, with chromosome rearrangements being the most common, resulting in ALK fusion with other genes including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3) , ALK / NPM1 (chromosome 5), ALK / SQSTM1 (chromosome 5), ALK / KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (X chromosome).?Probe DescriptionALK gene break apart probe uses orange labeled dye ALK gene (3 ' End) 2p23.2 region, and a green dye ALK gene (5' End) to mark 2p23.1-p23.2 region. ALK gene break apart probe can detect all ALK gene rearrangement, avoiding missed diagnosis caused by a single fusion gene (such as EML4-ALK). The 2013 edition of China anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer diagnosis expert consensus pointed out that adenocarcinoma, for age (60 years old), nonsmoking, EGFR, KRAS, HER2 or P53 in patients without NSCLC gene mutations, ALK gene positive rate is high as 30%~ 42%. Pathological studies suggest that the positive rate in signet-ring cell-containing mucinous or solid adenocarcinoma is higher than other types of lung adenocarcinoma. In 2013, CFDA approved XALKORI (Crizotinib) for targeted therapy of advanced ALK-positive non-small cell lung cancer, and the necessary condition for XALKORI (Crizotinib) drug treatment was FISH for the detection of ALK-positive non-small cell lung cancer. ALK-positive gene fusion patients are sensitive to XALKORI (Crizotinib) treatment.??Size SpecificationsReferences :l? Rodig SJ, et al. (2009) Clin Cancer Res 15: 5216-23.l? Sasaki T, et al. (2010) Eur J Cancer 46: 1773-80.l? Von Laffert M, et al. (2013) Lung Cancer 81: 200-6.
- 6q Probe (6q22)
ROS1 Gene Break Apart Rearrangement Detection ProbeProduct Advantages: ?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.?2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.?3.Reproducibility: Different laboratories test results are highly reproducible.??About ROS1The c-ros sarcoma tumor receptor-tyrosine kinase (ROS proto-oncogene 1, receptor tyrosine kinase, ROS1) is located on chromosome 6q21 and encodes a type of portable tyrosine kinase (RTK), which is involved in the growth, proliferation, differentiation and survival of cells. When the rearrangement of ROS1 gene occurs, the extracellular region is lost and the transmembrane and intracellular tyrosine kinase regions are retained. The rearrangement sites mainly occur in the 32~36 exons of the ROS1 gene. In NSCLC, ROS1 gene mainly fuses with SLC34A2, CD74, EZR, SDC4, etc., and continues to activate ROS1 tyrosine kinase region and downstream signaling pathways, thereby causing the occurrence and development of tumors.?Probe DescriptionROS1 gene break-apart rearrangement probe uses orange-red dye to mark the ROS1 gene 5' end region and green dye to mark ROS1 gene 3' end region. The ROS1 gene break-apart rearrangement can detect all ROS1 gene rearrangements, avoiding the missed diagnosis caused by a single fusion gene.?Detection SignificanceROS1 gene break-apart rearrangement occurs mostly in young, non-smoking lung adenocarcinoma patients. ROS1 rearrangements are different from other mutations such as EGFR, KRAS and ALK. The positive rate of ROS1 rearrangement is about 1.5%, and ROS1 rearrangement positive adenocarcinoma is poorly differentiated. ROS1 break-apart rearrangement positive patients are sensitive to XALKORI (Crizotinib) drugs.Size SpecificationsReferencesRimkunas VM, et al. (2012) Clin Cancer Res 18: 4449-57.Suehara Y, et al. (2012) Clin Cancer Res 18: 6599-608.Takeuchi K, et al. (2012) Nat Med 18: 378-81.
- HER-2 Amplification Probe
HER-2 Gene Amplification FISH ProbeProduct Advantages:?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.?2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.3.Reproducibility: Different laboratories test results are highly reproducible.About HER-2 geneHER-2 gene is located on the 17q12 of the human chromosome 17. It is one of the members of the epidermal growth factor receptor (EGFR/ErbB) family. It has tyrosine kinase activity and participates in the signal transduction of cell growth and differentiation. The carcinogenic mechanism of HER2 oncogene includes inhibiting apoptosis, promoting cell proliferation, increasing the invasiveness of tumor cells, and promoting tumor angiogenesis and lymphangiogenesis. 20% the expression of HER2 gene was positive in breast cancer and 12% gastric cancer.?Probe DescriptionThe HER2 gene amplification probe uses orange-red dye to mark the HER-2 gene region .and the green dye to mark the centromeric region of chromosome 17 (CEP17) .The HER2 gene tagged region is located at the 17q12-q21.1, and the CEP17 probe is labeled with a specific alpha satellite sequence.?Clinical SignificanceHER2 gene amplification can be found in many cancers such as breast cancer, hernia, small cell lung cancer, ovarian cancer, prostate cancer, colorectal cancer, salivary glands, etc., and is more common in breast cancer.Breast cancer is one of the most common malignant tumors in women. The incidence rate accounts for 7-10% of all malignant tumors in the whole body. About 20-35% breast cancer patients have HER2 gene amplification high protein expression. Breast cancer patients are recommended routine detection of HER2 gene status.Size Specifications?References Sauter G,et al.J Clin Oncol 27:1323-1333,2009.?Mass R,et al.Clinical Breast Cancer,Vol 6, No. 3, 240-246, 2005.?Allison M,Nature Biotechnology 28 (2):117-119, 2010.Press M,et al,Clinical Cancer Research 2005; 11(18) September 15, 2005
- TOP2A Amplification Probe
TOP2A Gene Amplification Detection ProbeProduct Advantages: ?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.?2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.?3.Reproducibility: Different laboratories test results are highly reproducible.??About TOP2A The TOP2A gene encodes DNA topoisomerase. This enzyme is involved in processes such as chromosome condensation, chromatid separation, and the release of torsional stress that occurs during DNA transcription and replication. The gene encoding this form, TOP2α, is located on chromosome 17, and the β gene is located on chromosome 3. Many mutations in this gene are associated with developmental resistance.?Probe DescriptionThe TOP2A gene amplification probe is labeled with orange dye for TOP2A gene region, and green dye for chromosome 17 centromere region (CEP17). The TOP2A gene tagged region is located at 17q21.2. The CEP17 probe adopts the α-satellite sequence and has a very high specificity. It does not generate hybrids with other chromosome centromeres.?Clinical SignificancePatients with abnormal TOP2A genes are predictive of a shorter relapse-free survival, and patients with TOP2A gene deletion have worse prognosis. The study of advanced breast cancer found that TOP2A gene anomalies are significantly associated with protein expression and tumor cell sensitivity to anthracyclines. Therefore, the detection of TOP2A gene status has guiding significance for the treatment and prognosis of breast cancer.?Size Specifications?Reference Brunello E,et al.(2012) Histopathology 60: 482-8.Razis E,et al.(2011) Breast Cancer Res Treat 128: 447-56.
- 8q Probe (8q24)
MYC Gene Amplification Detection ProbeProduct Advantages: ?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.?2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.?3.Reproducibility: Different laboratories test results are highly reproducible.??About MYC gene MYC proto-oncogene is located on chromosome 8q24 and encodes a transcription factor that regulates cell growth. It is mainly activated by amplification and chromosomal translocation rearrangement. MYC gene amplification is associated with the occurrence and development of a variety of tumors (including breast cancer, colon cancer, lung cancer, and hematopoietic tumors).?Probe DescriptionThe MYC gene amplification probe uses orange-red dye to mark the MYC gene region, and the green dye to mark the centromeric region of chromosome 8 (CEP8). The MYC gene tagged region is located at 8q24.21 and the CEP8 probe is labeled with a specific alpha satellite sequence.?Clinical Significance MYC gene amplification is a common phenomenon in tumors and can be seen in many malignant tumors such as breast cancer, nasopharyngeal cancer, and cervical cancer. The prognosis of breast cancer patients with MYC gene is poor.Size SpecificationsReferencesFromont G, et al. (2013) Hum Pathol 44: 1617-23.Mannuci S, et al. (2012) Adv Hematol 2012: 149780.
- PML/RARA gene fusion probe
PML/RARA gene fusion probe uses the PML probe labeled with orange red dye and the RARA probe labeled with green dye, the two probes can be combined with the target detection site by in situ hybridization. Normally (PML / RARA gene did not fuse), two orange and two green signals were displayed under fluorescence microscopy. When fusion genes exist, green and orange signals are reconstituted to form yellow fusion signals.PML/RARA fusion gene is a characteristic marker of acute promyelocytic leukemia (APL). PML / RARA fusion proteins inhibit the differentiation and maturation of promyelocytes through dominant negative inhibition, thereby blocking cell differentiation and leading to sustained proliferation. All trans retinoic acid (ATRA) and arsenic trioxide can degrade PML/RARA fusion protein, restore the function of wild type PML and RARA gene, relieve the inhibition of gene transcription, induce cell differentiation and apoptosis, so that APL can be effectively treated. The combined use of ATRA and chemotherapy can achieve a complete remission rate of APL for 90%~95%, More than 70% of the patients can survive for a long time.
- P53 Gene Amplification Detection Probe
The P53 Probe uses orange-red dye to mark the P53 gene region, and the green dye to mark the centromeric region of chromosome 17 (CEP17). The P53 gene tagged region is located at 17q13.1, and the CEP17 probe is labeled with a specific alpha satellite sequence.
The amplification and deletion of P53 gene indicate the poor prognosis of the tumor, it is insensitive to conventional chemotherapy, and the tumor is susceptible to metastasis.
- BCL6 Break Apart Probe
BCL6 Break Apart Probe
1. Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.
2. Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.
3. Reproducibility: Different laboratories test results are highly reproducible.
BCL6 Break Apart Probe is a dual-color break probe that is a mixture of two probes directly labeled to 3q27.3-q28. The green fluorescent directly labeled probe hybridizes with the 3q27.3 proximal BCL6 gene, while the orange is red. The fluorescently labeled probe directly hybridizes to the distal end of the BCL6 gene of the 3q27.3-q28 distal group.
Translocation of the BCL6 gene occurs in 6-26% of follicular lymphoma (FL) with higher incidence (44%) in grade 3 cases negative for t(14;18)(q32;q21). Rearrangement of the BCL6 gene is observed at a frequency of 15~40% in diffuse large B-cell lymphomas (DLBCL).
This probe is used to detect whether the BCL6 gene is broken and translocated. BCL6 gene fragmentation is an independent indicator for evaluating survival rate and recovery rate.
◆Clinical Significance of BCL6 Break Apart Probe
In diffuse large B-cell lymphoma, BCL6 gene can translocate with multiple genes, the incidence rate is 20%-40%; in follicular lymphoma, the incidence rate is 5-15%. Burkitt's lymphoma is morphologically suggestive of typical age, morphology, and immune characterization. If any of these three characteristics are not typical or have a history of follicular lymphoma with MYC gene breaks and BCL6 gene breaks, Gray area lymphoma between Burkitt/DLBCL should be diagnosed.
- Corona Virus Disease 2019 (CoViD-19) Nucleic Acid Detection Kit
This kit is used for the qualitative detection of the Corona virus Disease 2019 (CoViD-19) ORF1ab and N genes in vitro, helping clinicians to confirm whether suspected patients have C0ViD-19 infection.